Validation of diagnosis codes in healthcare databases in Taiwan, a literature review

Author:

Huang Yue‐Ton1ORCID,Wei Tiffaney12,Huang Ya‐Ling1ORCID,Wu Yu‐Pu13ORCID,Chan K. Arnold1ORCID

Affiliation:

1. Health Data Research Center National Taiwan University Taipei Taiwan

2. Epidemiology and Biostatistics, Master of Public Health (MPH) Boston University School of Public Health Boston Massachusetts USA

3. Department of Epidemiology Harvard T.H. Chan School of Public Health Boston Massachusetts USA

Abstract

AbstractPurposeTo compile validation findings of diagnosis codes and related algorithms for health outcomes of interest from National Health Insurance (NHI) or electronic medical records in Taiwan.MethodsWe carried out a literature review of English articles in PubMed® and Embase from 2000 through July 2022 with appropriate search terms. Potentially relevant articles were identified through review of article titles and abstracts, full text search of methodology terms “validation”, “positive predictive value”, and “algorithm” in Subjects & Methods (or Methods) and Results sections of articles, followed by full text review of potentially eligible articles.ResultsWe identified 50 published reports with validation findings of diagnosis codes and related algorithms for a wide range of health outcomes of interest in Taiwan, including cardiovascular diseases, stroke, renal impairment, malignancy, diabetes, mental health diseases, respiratory diseases, viral (B and C) hepatitis, and tuberculosis. Most of the reported PPVs were in the 80% ~ 99% range. Assessment of algorithms based on ICD‐10 systems were reported in 8 articles, all published in 2020 or later.ConclusionsInvestigators have published validation reports that may serve as empirical evidence to evaluate the utility of secondary health data environment in Taiwan for research and regulatory purpose.

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference101 articles.

1. U.S. Food and Drug Administration.Framework for FDA's Real‐World Evidence Program. December 2018 (Accessed Jan 4 2023).https://www.fda.gov/media/120060/download

2. U.S. Food and Drug Administration.Real‐world data: assessing electronic health records and medical claims data to support regulatory decision‐ making for drug and biological products. Draft Guidance September 2021. (Accessed Jan 4 2023).https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/real‐world‐data‐assessing‐electronic‐health‐records‐and‐medical‐claims‐data‐support‐regulatory

3. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis

4. Gastric and Duodenal Safety of Daily Alendronate

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3